Newsletter | April 7, 2016

04.07.16 -- How Can Biosimilar Companies Make Money?

Biosimilar Development
 
Featured Editorial
How To Build A Biosimilar Business: And Make Money, Too
By Anna Rose Welch, Editor, Biosimilar Development   By Anna Rose Welch, Editor, Biosimilar Development
Today, many companies are focusing on how they can tackle the regulatory challenges and get a biosimilar approved in the United States. However, there is one important question that, surprisingly, can get overlooked: How can a company in the biosimilar space compete and actually make money doing it?
4 Key Trends In Biopharmaceutical Manufacturing In 2016
By Eric Langer, President and Managing Partner, BioPlan Associates, Inc.   By Eric Langer, President and Managing Partner, BioPlan Associates, Inc.
One of the most important trends to emerge from preliminary results of this year’s survey is the increased attention paid to continuous bioprocessing. Integrated, broad upstream and downstream technologies remain to be developed and commercialized. Despite this lack of viable options, there is a groundswell of enthusiasm for the concept.
Where Does Continuous Bioprocessing Feature In CMOs' Plans?
By Dr. Nick Hutchinson, Contributor   By Dr. Nick Hutchinson, Contributor
Despite the fact continuous biomanufacturing methods are receiving considerable industry attention and interest, it’s hard to identify a CMO that is attempting to emphasize its position as an expert in this field. What might the causes be that would lead to a discrepancy between apparent demand for fully continuous capacity and the supply from biomanufacturing CMOs?
Systems Engineering For Complex Portable Medical Device Development
Phillips-Medisize   Phillips-Medisize
As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount.
News Headlines
IMS Health: Surge In Biosimilars To Drive Significant Change In Health System Costs, Patient Access, And Competition By 2020
GPhA, AHIP Urge Supreme Court To Preserve Inter Partes Review, Expedite Patient Access To Affordable Generic Drugs
FLIXABI, An Infliximab Biosimilar Candidate Referencing Remicade, Receives Positive CHMP Opinion
Biosimilars Blog
 
  Read this week’s blog posts on:
• Samsung Bioepis Second Biosimilar Receives CHMP Approval
• FDA Releases Biosimilar Labeling Guidance
• Sandoz, AbbVie Squaring Off Over Interchangeability

For these and other headlines, click here.
Connect With Biosimilar Development:
Twitter